Ian S. Dayes

5.4k total citations · 1 hit paper
65 papers, 2.0k citations indexed

About

Ian S. Dayes is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ian S. Dayes has authored 65 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 19 papers in Radiation and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ian S. Dayes's work include Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Advanced Radiotherapy Techniques (19 papers). Ian S. Dayes is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Advanced Radiotherapy Techniques (19 papers). Ian S. Dayes collaborates with scholars based in Canada, United States and Kuwait. Ian S. Dayes's co-authors include Himu Lukka, Jim A. Julian, Mark N. Levine, Jinka Sathya, Ian Davis, Dean Daya, Qing Guo, David D’Souza, Howard M. Sandler and Deborah Watkins Bruner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

Ian S. Dayes

60 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

2016 415 citations W. Robert Lee, James J. Dignam et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian S. Dayes Canada	19	1.1k	630	559	399	376	65	2.0k
D.A. Loblaw Canada	29	2.5k 2.2×	877 1.4×	587 1.1×	643 1.6×	487 1.3×	88	3.4k
Giulio Francolini Italy	22	796 0.7×	340 0.5×	312 0.6×	226 0.6×	433 1.2×	120	1.3k
Stéphanie Peeters Netherlands	22	2.2k 1.9×	1.7k 2.7×	378 0.7×	301 0.8×	901 2.4×	66	2.9k
Scott C. Morgan Canada	19	1.2k 1.0×	389 0.6×	305 0.5×	308 0.8×	337 0.9×	100	1.7k
Margot Lehman Australia	19	496 0.4×	404 0.6×	324 0.6×	186 0.5×	272 0.7×	70	1.1k
Marian Loffredo United States	27	2.7k 2.4×	649 1.0×	370 0.7×	441 1.1×	300 0.8×	82	3.0k
J.F. Lester United Kingdom	20	1.0k 0.9×	161 0.3×	638 1.1×	158 0.4×	243 0.6×	84	1.5k
Rolando Maria D’Angelillo Italy	22	1.1k 1.0×	406 0.6×	464 0.8×	288 0.7×	523 1.4×	112	1.8k
J. Frank Wilson United States	23	404 0.4×	389 0.6×	519 0.9×	352 0.9×	384 1.0×	81	1.6k
J.B. Dubois France	14	3.0k 2.7×	760 1.2×	545 1.0×	621 1.6×	264 0.7×	40	3.6k

Countries citing papers authored by Ian S. Dayes

Since Specialization

Citations

This map shows the geographic impact of Ian S. Dayes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian S. Dayes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian S. Dayes more than expected).

Fields of papers citing papers by Ian S. Dayes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian S. Dayes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian S. Dayes. The network helps show where Ian S. Dayes may publish in the future.

Co-authorship network of co-authors of Ian S. Dayes

This figure shows the co-authorship network connecting the top 25 collaborators of Ian S. Dayes. A scholar is included among the top collaborators of Ian S. Dayes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian S. Dayes. Ian S. Dayes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Shuang, Hyunnam Ryu, J. Proudfoot, et al.. (2025). Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.. Journal of Clinical Oncology. 43(5_suppl). 308–308. 2 indexed citations

Dayes, Ian S., Charles Catton, Amy Liu, et al.. (2025). Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer. European Urology Oncology. 9(1). 26–36. 1 indexed citations

Gelmon, Karen A., Jean-François Boileau, Christine Brezden‐Masley, et al.. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting. Current Oncology. 31(11). 6536–6567. 1 indexed citations

Cao, Jeffrey, Jean-François Boileau, Karen A. Gelmon, et al.. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer. Current Oncology. 31(11). 7226–7243. 2 indexed citations

Lee, W. Robert, James J. Dignam, Mahul B. Amin, et al.. (2024). Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 42(20). 2377–2381. 11 indexed citations

Lee, W. Robert, James J. Dignam, Mahul B. Amin, et al.. (2023). Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). S3–S4.

Dayes, Ian S., et al.. (2023). 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. Radiotherapy and Oncology. 186. S53–S53.

Spratt, Daniel E., Huei–Chung Huang, Jeff M. Michalski, et al.. (2022). Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.. Journal of Clinical Oncology. 40(6_suppl). 269–269. 4 indexed citations

Dayes, Ian S., Sameer Parpia, Christopher Thome, et al.. (2022). Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. Advances in Radiation Oncology. 8(1). 101066–101066. 1 indexed citations

10.

Mesci, Aruz, et al.. (2021). The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments. Clinical Genitourinary Cancer. 20(1). e25–e38. 6 indexed citations

11.

Lukka, Himanshu, Ian S. Dayes, James R. Wright, et al.. (2020). A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18(4). e410–e415. 7 indexed citations

12.

Kapoor, Anil, Yuding Wang, Som D. Mukherjee, et al.. (2019). Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. 22(4). 437–437. 1 indexed citations

13.

Dayes, Ian S., Sameer Parpia, Jim A. Julian, et al.. (2017). Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. International Journal of Radiation Oncology*Biology*Physics. 99(1). 90–93. 69 indexed citations

14.

Lee, W. Robert, James J. Dignam, Mahul B. Amin, et al.. (2016). Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 34(20). 2325–2332. 415 indexed citations breakdown →

15.

Bruner, Deborah Watkins, Stephanie L. Pugh, W. Robert Lee, et al.. (2016). NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results. International Journal of Radiation Oncology*Biology*Physics. 96(2). S2–S3. 4 indexed citations

16.

Gillis, Daniel, Colin E. Webber, Jennifer A. Lemon, et al.. (2015). Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans. Dose-Response. 13(4). 3579060736–3579060736. 10 indexed citations

17.

Elit, L., Anthony Fyles, Chu‐Shu Gu, et al.. (2015). The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.. Journal of Clinical Oncology. 33(15_suppl). 5523–5523. 4 indexed citations

18.

Oremus, Mark, Kathryn Walker, Ian S. Dayes, & Parminder Raina. (2010). Diagnosis and Treatment of Secondary Lymphedema. 14 indexed citations

19.

Boreham, Douglas R., et al.. (2009). Radiation-Induced Lymphocyte Apoptosis to Predict Radiation Therapy Late Toxicity in Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 74(5). 1424–1430. 60 indexed citations

20.

Dayes, Ian S., et al.. (2006). Individual Radiosensitivity and Its Relevance to Health Physics. ScholarWorks@UMassAmherst (University of Massachusetts Amherst). 942. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact